"Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes
Sondel, P.M.; Hank, J.A.; Kohler, P.C.; Chen, B.P.; Sosman, J.
Progress in Clinical and Biological Research 288: 151-160
1989
ISSN/ISBN: 0361-7742 PMID: 2654949 Document Number: 344062
Document emailed within 1 workday
Related Documents
Marincola, F.M.; Da Pozzo, L.F.; Drucker, B.J.; Holder, W.D. 1990: Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model Surgery 108(5): 919-929Kaufmann, Y.; Levanon, M.; Davidsohn, J.; Ramot, B. 1987: Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity Journal of Immunology 139(3): 977-982
Stewart, J.A.; Belinson, J.L.; Moore, A.L.; Dorighi, J.A.; Grant, B.W.; Haugh, L.D.; Roberts, J.D.; Albertini, R.J.; Branda, R.F. 1990: Phase i trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer Cancer Research 50(19): 6302-6310
Lamers, H.J.; Gratama, J.W.; van Putten, W.L.; Stoter, G.; Bolhuis, R.L. 1991: Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes Cancer Research 51(9): 2324-2328
Blacklock, J.B.; Grimm, E.A. 1989: Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system Immunology Series 48: 93-99
Yasumoto, K.; Mivazaki, K.; Nagashima, A.; Ishida, T.; Kuda, T.; Yano, T.; Sugimachi, K.; Nomoto, K. 1987: Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer Cancer Research 47(8): 2184-2187
Thompson, J.A.; Benyunes, M.C.; Bianco, J.A.; Fefer, A. 1993: Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells Seminars in Oncology 20(6 Suppl 9: 46-51
Bout, D.T.; Joseph, M.; David, J.R.; Capron, A.R. 1981: In vitro killing of S. mansoni schistosomula by lymphokine-activated mouse macrophages Journal of Immunology 127(1): 1-5
Walle, A.J.; Wang, J.; Novogrodsky, A.; Suthanthiran, M.; Gordon, B.; Rubin, A.L.; Stenzel, K.H. 1988: Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer Cancer Detection and Prevention 12(1-6): 395-411
Glassman, A.B. 1989: Interleukin-2 and lymphokine activated killer cells: promises and cautions Annals of Clinical and Laboratory Science 19(1): 51-55
Wang, Z.P.; Zheng, R.L.; Chen, Y.R.; Liu, G.D. 1997: Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro Zhongguo Yao Li Xue Bao 18(6): 522-524
Kanai, T.; Monden, M.; Takeda, T.; Gotoh, M.; Sakon, M.; Umeshita, K.; Hasuike, Y.; Sakita, I.; Nakano, H.; Yoshida, T. 1993: Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1457-1460
Kierszenbaum, F.; Lopez, H.M.; Sztein, M.B. 1996: Trypanosoma cruzi downregulates the production of interleukin-2, interferon-gamma, interleukin-4 and interleukin-5 by activated human lymphocytes Journal of Parasitology 82(4): 652-656
Takahashi, M. 1991: Specific antitumor effect of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of interleukin-2 (IL-2) Nihon Geka Gakkai Zasshi 92(3): 247-256
Marcus, S.L.; Dutcher, J.P.; Paietta, E.; Ciobanu, N.; Strauman, J.; Wiernik, P.H.; Hutner, S.H.; Frank, O.; Baker, H. 1987: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells Cancer Research 47(15): 4208-4212
Shiloni, E.; Lafreniere, R.; Mulé, J.J.; Schwarz, S.L.; Rosenberg, S.A. 1986: Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice Cancer Research 46(11): 5633-5640
Bouet-Toussaint, F.; Genetel, N.; Rioux-Leclercq, N.; Bansard, J.Y.; Levêque, J.; Guillé, F.; Patard, J.J.; Lesimple, T.; Catros-Quemener, V. 2000: Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer European Cytokine Network 11(2): 217-224
Brooks, B.; Rees, R.C. 1988: Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity Clinical and Experimental Immunology 74(2): 162-165
Sznol, M.; Clark, J.W.; Smith, J.W.; Steis, R.G.; Urba, W.J.; Rubinstein, L.V.; VanderMolen, L.A.; Janik, J.; Sharfman, W.H.; Fenton, R.G. 1992: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma Journal of the National Cancer Institute 84(12): 929-937
Pearson, R.D.; Steigbigel, R.T. 1981: Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes Journal of Immunology 127(4): 1438-1443